由于股东的反对,韩国生物制药公司Celltrion中止了与附属Celltrion制药公司的合并。 South Korean biopharma firm Celltrion aborts merger with affiliate Celltrion Pharm due to shareholder opposition.

由于股东分歧,韩国生物制药公司Celltrion放弃与附属Celltrion制药公司的兼并计划;36.2%反对,55.1%弃权,只有8.7%支持兼并。 South Korean biopharma firm Celltrion abandons merger plan with affiliate Celltrion Pharm due to shareholder disagreements; 36.2% opposed, 55.1% abstained, and only 8.7% supported the merger. 尽管得到Celltrion制药公司股东的多数批准,但由于缺乏支持,导致作出这一决定。 Despite majority approval from Celltrion Pharm shareholders, lack of support led to the decision. 通过合并,Celltrion的目标是成为全球生物仿制药和新药开发的制药商. Celltrion aimed to become a global drugmaker in biosimilars and new drug development through mergers.